Analysts Expect Assembly Biosciences Inc (ASMB) Will Announce Earnings of -$1.07 Per Share

Wall Street brokerages expect that Assembly Biosciences Inc (NASDAQ:ASMB) will report earnings per share of ($1.07) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Assembly Biosciences’ earnings, with estimates ranging from ($1.15) to ($0.96). Assembly Biosciences reported earnings per share of ($0.80) in the same quarter last year, which would suggest a negative year over year growth rate of 33.8%. The company is expected to report its next earnings report on Monday, May 13th.

On average, analysts expect that Assembly Biosciences will report full-year earnings of ($4.37) per share for the current financial year, with EPS estimates ranging from ($5.19) to ($3.74). For the next year, analysts anticipate that the company will post earnings of ($5.33) per share, with EPS estimates ranging from ($5.80) to ($4.85). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The company had revenue of $3.74 million during the quarter, compared to the consensus estimate of $3.69 million.

ASMB has been the subject of a number of research reports. BidaskClub raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, Chardan Capital reissued a “hold” rating and issued a $30.00 price target on shares of Assembly Biosciences in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $43.00.

Assembly Biosciences stock traded up $0.01 during mid-day trading on Friday, reaching $16.09. The company had a trading volume of 973 shares, compared to its average volume of 307,858. Assembly Biosciences has a 52 week low of $13.13 and a 52 week high of $48.91. The company has a market cap of $400.37 million, a PE ratio of -3.94 and a beta of 1.60.

Hedge funds have recently made changes to their positions in the stock. Tibra Equities Europe Ltd bought a new position in Assembly Biosciences during the 1st quarter valued at about $918,000. Man Group plc lifted its holdings in Assembly Biosciences by 19.6% during the 3rd quarter. Man Group plc now owns 36,042 shares of the biopharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 5,904 shares during the last quarter. Marshall Wace LLP bought a new position in Assembly Biosciences during the 3rd quarter valued at about $11,224,000. Victory Capital Management Inc. lifted its holdings in Assembly Biosciences by 3.4% during the 4th quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after purchasing an additional 17,669 shares during the last quarter. Finally, New York State Common Retirement Fund increased its position in Assembly Biosciences by 15.3% in the 4th quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 3,100 shares in the last quarter. 83.74% of the stock is owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: Balanced Fund

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.